HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
about
Recent advances in the development of Aurora kinases inhibitors in hematological malignanciesHistone acetylation: novel target for the treatment of acute lymphoblastic leukemiaParadoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphomaSynergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanismThe synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Histone deacetylase inhibitors: emerging mechanisms of resistance.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Rational Combinations of Targeted Agents in AMLProteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer.Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity.PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaRedox control of leukemia: from molecular mechanisms to therapeutic opportunities.Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase.SIAH proteins: critical roles in leukemogenesis.HDAC inhibitor-based therapies: can we interpret the code?Pharmacogenomic considerations of xenograft mouse models of acute leukemia.While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia.STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Multi-kinase inhibitors, AURKs and cancer.How do tumor cells respond to HDAC inhibition?Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
P2860
Q26775723-248476BB-0657-40A7-9170-A83D3C58D32CQ26778780-8A38D94B-5D6D-48F6-A529-A30968E79C3DQ28535447-796A04DC-780A-4C95-89B9-D1759251DF57Q33761796-5F7AFA96-2210-4B52-9AB9-E6A174AF4A46Q33983255-10F29FF2-FF9B-4C44-9DCA-A7FEF05EE34CQ34326588-4196816E-271B-4938-9DD7-5CB3BBB80841Q34393767-B5FCABBE-8573-4C5D-9871-A84BEC45F0E4Q35111380-D10DAEFE-9D64-4964-88D4-4B877DDC9DD3Q35117747-AED4C177-03D5-4E36-A645-86D03E35EB66Q35176353-917C1165-1C3F-430A-9A04-3B2CB6A77EFCQ35592607-F280C72C-621E-485C-999B-F241802435F6Q35740894-73B090C4-F4C5-4D9B-9EFF-429BC5AFBDE2Q35750491-DAD8D846-5BA6-4543-B55E-4A521803BD62Q35882968-E0A1822C-F3D7-40DD-AF2E-78FF84342400Q35988744-AFC010AD-FFCE-44AC-9E52-FBF1CA696D9EQ36002405-B1829475-E57E-477F-8C6A-4714F7CE8C9CQ36544946-82BD5E48-8D5F-4873-A992-32769A6DF031Q36547224-EB9C62F5-A9E0-4AB2-9578-4F58C75AC7B9Q36646486-9FA121E6-CC46-472E-96A6-20E455E9A711Q37104343-7BEB1DB1-E9A8-4A7F-A69E-383DE636433CQ38049544-AD029C04-5445-46E3-A686-3E344A21528AQ38058971-90E6C5D3-4529-47B4-844D-B92DE274E3B2Q38061500-20BC6FCC-D92F-4A5D-873D-682106641863Q38066406-1C23E8FE-99DD-4520-9377-3EB093E5ED27Q38141135-8287B71B-F6D8-4514-8549-3DD219B00D40Q38177821-183A0516-D786-4A7C-A1F7-A40C4BA815BBQ38223271-3A43CE44-C53F-4FEA-8C72-415D584410ADQ38240733-A78C9ECB-E209-429E-9609-33CD69E30887Q38710509-CBA5929E-3447-45DB-A40A-BA16C12225A7Q38796360-96241915-8C01-44C5-82DE-967CC7554C8EQ38817005-98DCFF38-CE0F-43DC-A41E-048C1125BB82Q38900285-335E0128-B23C-4DD0-9370-E69EA8B0B34EQ40063670-E217867A-2BC3-49EA-B3B1-2F2651856D70Q50128200-146B3F4E-E28D-4165-8559-3FEDFE2163FBQ54498929-587FE4CE-CD5C-4880-ACF0-499C046D1526
P2860
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@ast
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@en
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@nl
type
label
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@ast
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@en
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@nl
prefLabel
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@ast
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@en
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@nl
P2093
P2860
P1476
HDAC inhibitors potentiate the ...... ia cells in vitro and in vivo.
@en
P2093
Elisa Attkisson
Lora Kramer
Markus Muschen
Nguyen Nguyen
Nicholas Jordan
Nikhil Kolluri
Steven Grant
Tri Nguyen
P2860
P304
P356
10.1158/1078-0432.CCR-11-0234
P407
P577
2011-04-07T00:00:00Z